Gilteritinib Monotherapy as a Transplant Bridging Option for a Patient with <i>FLT3</i>-Mutated Acute Promyelocytic Leukemia Who Developed a Second Relapse after All-Trans Retinoic Acid + Chemotherapy, Arsenic Trioxide, and High-Dose Cytarabine Therapy

<div>Clinical course of the patient during administration of gilteritinib. The details are described in the case report. WBC: white blood cell; Plt: platelet; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase.</div>

Case Reports in Hematology

fig1

Figure 1

Figure 1: Gilteritinib Monotherapy as a Transplant Bridging Option for a Patient with <i>FLT3</i>-Mutated Acute Promyelocytic Leukemia Who Developed a Second Relapse after All-Trans Retinoic Acid + Chemotherapy, Arsenic Trioxide, and High-Dose Cytarabine Therapy 

Figure 1 | Gilteritinib Monotherapy as a Transplant Bridging Option for a Patient with FLT3-Mutated Acute Promyelocytic Leukemia Who Developed a Second Relapse after All-Trans Retinoic Acid + Chemotherapy, Arsenic Trioxide, and High-Dose Cytarabine Therapy 